Aralez resubmits to FDA New Drug Application for YOSPRALA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aralez Pharma (ARLZ) Misses Q4 EPS by 12c; Announces Resubmission of YOSPRALA NDA
March 15, 2016 7:52 AM EDTAralez Pharma (NASDAQ: ARLZ) reported Q4 EPS of ($0.40), $0.12 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $5.97 million versus the consensus estimate of $10.41 million.
GUIDANCE:
Aralez Pharma sees FY2016 revenue of $48-58 million, versus the consensus of $54.8 million.
Update:
Aralez also announced that it has resubmitted to the U.S. Food and Drug Administration ("FDA") the New Drug Application ("NDA") for its investigational candidate, YOSPRALA (PA32540/PA8140) for the secondary... More
